메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
김성옥 (인제대학교)
저널정보
한국보건의료기술평가학회 보건의료기술평가 보건의료기술평가 제4권 제2호
발행연도
2016.12
수록면
58 - 66 (9page)

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
The growth rate of pharmaceutical expenditures covered by the National Health Insurance had been rapidly growing and also its proportion among the health expenditures had been compara- tively high (29.15% in 2011). This study presented a roadmap to contain pharmaceutical expendi- tures under the National Health Insurance System composed of five agenda, which were initiated by the National Health Insurance Service (NHIS) in the perspective of insurer in 2012. Five agenda com- posed of strengthening of the negotiation power of the insurer and diversification of risk sharing arrangement, global pharmaceutical budget system, reference pricing system, pharmaceutical ten- dering system, and public fund for orphan drugs, which were selected from the discussion among the staff in the NHIS. Then expert opinion survey were conducted to investigate stakeholers’ antici- pated impact of each 5 agenda with the criteria of pharmaceutical expenditure control, sustainablity and equity, efficiency, availability, accessibility, quality and health outcomes, satisfaction of consum- er and patient, and objective of pharmaceutical company (R&D and innovation). And anticipated in- troduction time of these agenda, policy compliance of stakeholders. 19 experts from academic, gov- ernment, pharmaceutical company, doctors, pharmacist and consumer and patient group. The roadmap to control pharmaceutical expenditures composed of 5 agenda initiated by the NHIS were presented in detail as result of experts’ opinion.

목차

등록된 정보가 없습니다.

참고문헌 (24)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0